ArticleEBioMedicine2025

Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study).

Lindsay Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.